Visit Exec Edge Research for Full Report
By Exec Edge Research
Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.
As we highlighted in our 66-page initiation report last week (download here), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.
Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.
